Anticancer, Inc.
Preclinical contract research organization focused on oncology model development and preclinical testing. Core competencies include development and maintenance of patient-derived and orthotopic tumor models, multicolor fluorescent-protein–labeled cell lines and transgenic animal hosts for non-invasive and intravital imaging, sponge-supported three-dimensional explant (histoculture) assays for drug-response testing with documented clinical correlations, recombinant enzyme expression and formulation including PEG conjugation studies, enzyme-based diagnostic assays, and preclinical evaluation of tumor-targeting bacteria and fluorescence-guided surgical approaches. The organization maintains an extensive peer-reviewed publication record describing methods, validation studies and clinical correlations.
Industries
Nr. of Employees
small (1-50)
Anticancer, Inc.
San Diego, California, United States, North America
Patents
Composition for the treatment of COVID-19 infection, and a method of treatment
US-12023370-B2
View DetailsTransplantation method to increase the establishment rate of human tumors in immunodeficient mice
US-11871731-B2
View DetailsOrally administered composition to lower serum methionine levels and method of use
US-11001826-B2
View Details
Composition for the treatment of COVID-19 infection, and a method of treatment
US-12023370-B2
View DetailsTransplantation method to increase the establishment rate of human tumors in immunodeficient mice
US-11871731-B2
View DetailsOrally administered composition to lower serum methionine levels and method of use
US-11001826-B2
View DetailsProducts
Multicolor fluorescent-protein–expressing transgenic animals
Transgenic animal strains with tissue-linked or ubiquitous multicolor fluorescent-protein expression supplied for imaging tumor–host interactions and angiogenesis studies.
Fluorescent-protein–expressing cancer cell lines
Catalog of cancer cell lines stably expressing fluorescent proteins for implantation, intravital imaging and ex vivo studies.
Recombinant enzymes for preclinical research
Recombinant enzymes for preclinical studies of metabolic-dependency strategies, available in research quantities and evaluated in combination-treatment and PEGylation studies.
HDRA-compatible sponge-matrix materials and service
Sponge-matrix histoculture materials and laboratory service to culture patient tumor fragments for ex vivo drug-sensitivity testing and image-based endpoints.
Multicolor fluorescent-protein–expressing transgenic animals
Transgenic animal strains with tissue-linked or ubiquitous multicolor fluorescent-protein expression supplied for imaging tumor–host interactions and angiogenesis studies.
Fluorescent-protein–expressing cancer cell lines
Catalog of cancer cell lines stably expressing fluorescent proteins for implantation, intravital imaging and ex vivo studies.
Recombinant enzymes for preclinical research
Recombinant enzymes for preclinical studies of metabolic-dependency strategies, available in research quantities and evaluated in combination-treatment and PEGylation studies.
HDRA-compatible sponge-matrix materials and service
Sponge-matrix histoculture materials and laboratory service to culture patient tumor fragments for ex vivo drug-sensitivity testing and image-based endpoints.
Services
On-site contract services including generation and maintenance of PDOX/PDX, syngeneic and transgenic models, in vivo efficacy and imaging studies, and custom model development for drug discovery and preclinical evaluation.
Sponge-supported 3-D explant culture service to assess patient tumor fragment drug sensitivity using metabolic, proliferation and imaging endpoints. Services include reporting of correlations with in vivo and clinical outcomes based on an extensive bibliography of validation studies.
Distribution of fluorescent-protein–expressing cell lines and transgenic animal strains for imaging, implantation and model development.
Provision of recombinant enzymes for research use, including PEGylated formulations and guidance on dosing used in preclinical studies.
Development and supply of enzyme-based assays for low-volume plasma/serum biomarker testing suitable for research laboratories.
On-site contract services including generation and maintenance of PDOX/PDX, syngeneic and transgenic models, in vivo efficacy and imaging studies, and custom model development for drug discovery and preclinical evaluation.
Sponge-supported 3-D explant culture service to assess patient tumor fragment drug sensitivity using metabolic, proliferation and imaging endpoints. Services include reporting of correlations with in vivo and clinical outcomes based on an extensive bibliography of validation studies.
Distribution of fluorescent-protein–expressing cell lines and transgenic animal strains for imaging, implantation and model development.
Provision of recombinant enzymes for research use, including PEGylated formulations and guidance on dosing used in preclinical studies.
Development and supply of enzyme-based assays for low-volume plasma/serum biomarker testing suitable for research laboratories.
Expertise Areas
- Sponge-supported 3-D histoculture drug-response assays with clinical correlation
- Patient-derived orthotopic and xenograft model development (PDOX/PDX)
- Multicolor fluorescence imaging and intravital microscopy
- Recombinant enzyme production, formulation and PEG conjugation
Key Technologies
- Sponge-supported 3-D explant histoculture
- Patient-derived orthotopic xenograft models
- Multicolor fluorescent-protein labeling
- Whole-body fluorescence imaging
News & Updates
Presentation on application of patient-derived orthotopic xenograft models to sarcoma therapy at the ISOLS meeting (UCLA).
Compiled bibliography and methodological overview covering sponge-supported 3-D histoculture methods, assay endpoints and clinical correlation studies spanning multiple decades.
Extensive compiled bibliography covering PDOX/PDX, histoculture drug-response assays, methioninase research, fluorescent models and related preclinical topics.
Over multiple decades, numerous peer-reviewed publications and book chapters document development, validation and clinical correlations of histoculture assays, imaging methods, model development and preclinical evaluations.
Prospective and retrospective clinical correlation studies reported using sponge-supported histoculture methods demonstrating prediction of treatment response and progression-free survival in specific clinical cohorts.
Referenced documents and press coverage concerning intellectual property and method documentation related to orthotopic implantation techniques used to generate clinically relevant models.
Presentation on application of patient-derived orthotopic xenograft models to sarcoma therapy at the ISOLS meeting (UCLA).
Compiled bibliography and methodological overview covering sponge-supported 3-D histoculture methods, assay endpoints and clinical correlation studies spanning multiple decades.
Extensive compiled bibliography covering PDOX/PDX, histoculture drug-response assays, methioninase research, fluorescent models and related preclinical topics.
Over multiple decades, numerous peer-reviewed publications and book chapters document development, validation and clinical correlations of histoculture assays, imaging methods, model development and preclinical evaluations.
Prospective and retrospective clinical correlation studies reported using sponge-supported histoculture methods demonstrating prediction of treatment response and progression-free survival in specific clinical cohorts.
Referenced documents and press coverage concerning intellectual property and method documentation related to orthotopic implantation techniques used to generate clinically relevant models.